miR‑25 expression is upregulated in pancreatic ductal adenocarcinoma and promotes cell proliferation by targeting ABI2

Lu,Huimin; Zhang,Ling; Lu,Shan; Yang,Dujiang; Ye,Jun; Li,Mao; Hu,Weiming

doi:10.3892/etm.2020.8595

miR‑25 expression is upregulated in pancreatic ductal adenocarcinoma and promotes cell proliferation by targeting ABI2

Authors:
- Huimin Lu
- Ling Zhang
- Shan Lu
- Dujiang Yang
- Jun Ye
- Mao Li
- Weiming Hu
View Affiliations

Affiliations: Department of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR. China
Published online on: March 11, 2020 https://doi.org/10.3892/etm.2020.8595
Pages: 3384-3390

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) are reported to play a critical role in the regulation of cancer cell proliferation; however, the role of microRNA‑25 (miR‑25) in pancreatic ductal adenocarcinoma (PDAC) remains unclear. In the present study, the role of miR‑25 in PDAC cell proliferation was investigated. Upregulated expression of miR‑25 was found in PDAC tissues and cell lines by reverse transcription‑quantitative PCR. Cell proliferation was significantly enhanced by overexpression of miR‑25 as shown by CCK‑8 assay results. Meanwhile, overexpression of miR‑25 also promoted G1‑to‑S phase transition of the cell cycle in Aspc‑1 cells via flow cytometry analysis. However downregulation of miR‑25 inhibited the tumor cell proliferation and cell cycle transition. Online software was used to predict the target gene for miR‑25 and luciferase reporter assay confirmed that Abl interactor 2 (ABI2) was a target of miR‑25 via direct binding of its 3' untranslated region with miR‑25. Moreover, results of the western blot analysis demonstrated that miR‑25 negatively regulated the expression of ABI2 at the protein level. In addition, introduction of ABI2 mRNA into cells overexpressing miR‑25 attenuated the carcinogenic effects of miR‑25. In conclusion, these findings demonstrate that miR‑25 plays an oncogenic role and promotive role in PDAC cell proliferation via targeting of ABI2.

View Figures

View References

1	Hariharan D, Saied A and Kocher HM: Analysis of mortality rates for pancreatic cancer across the world. HPB (Oxford). 10:58–62. 2008.PubMed/NCBI View Article : Google Scholar
2	Garrido-Laguna I and Hidalgo M: Pancreatic cancer: From state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 12:319–334. 2015.PubMed/NCBI View Article : Google Scholar
3	Adamska A, Domenichini A and Falasca M: Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int J Mol Sci. 18(E1338)2017.PubMed/NCBI View Article : Google Scholar
4	Vincent A, Herman J, Schulick R, Hruban RH and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.PubMed/NCBI View Article : Google Scholar
5	Garzon R, Marcucci G and Croce CM: Targeting microRNAs in cancer: Rationale, strategies and challenges. Nat Rev Drug Discov. 9:775–789. 2010.PubMed/NCBI View Article : Google Scholar
6	Friedman RC, Farh KKH, Burge CB and Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19:92–105. 2009.PubMed/NCBI View Article : Google Scholar
7	Garofalo M and Croce CM: microRNAs: Master Regulators as Potential Therapeutics in Cancer. Annu Rev Pharmacol Toxicol. 51:25–43. 2011.PubMed/NCBI View Article : Google Scholar
8	Zhang Y, Li M, Wang H, Fisher WE, Lin PH, Yao Q and Chen C: Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg. 33:698–709. 2009.PubMed/NCBI View Article : Google Scholar
9	Khan MA, Zubair H, Srivastava SK, Singh S and Singh AP: Insights Into the Role of microRNAs in Pancreatic Cancer Pathogenesis: Potential for Diagnosis, Prognosis, and Therapy. Adv Exp Med Biol. 889:71–87. 2015.PubMed/NCBI View Article : Google Scholar
10	Wang Z, Wang N, Liu P, Chen Q, Situ H, Xie T, Zhang J, Peng C, Lin Y and Chen J: MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin. Oncotarget. 5:7013–7026. 2014.PubMed/NCBI View Article : Google Scholar
11	Zhang H, Zuo Z, Lu X, Wang L, Wang H and Zhu Z: miR-25 regulates apoptosis by targeting Bim in human ovarian cancer. Oncol Rep. 27:594–598. 2012.PubMed/NCBI View Article : Google Scholar
12	Feng S, Pan W, Jin Y and Zheng J: miR-25 promotes ovarian cancer proliferation and motility by targeting LATS2. Tumour Biol. 35:12339–12344. 2014.PubMed/NCBI View Article : Google Scholar
13	Zhao H, Wang Y, Yang L, Jiang R and Li W: miR-25 promotes gastric cancer cells growth and motility by targeting RECK. Mol Cell Biochem. 385:207–213. 2014.PubMed/NCBI View Article : Google Scholar
14	Li BS, Zuo QF, Zhao YL, Xiao B, Zhuang Y, Mao XH, Wu C, Yang SM, Zeng H, Zou QM, et al: MicroRNA-25 promotes gastric cancer migration, invasion and proliferation by directly targeting transducer of ERBB2, 1 and correlates with poor survival. Oncogene. 34:2556–2565. 2015.PubMed/NCBI View Article : Google Scholar
15	Li Q, Zou C, Zou C, Han Z, Xiao H, Wei H, Wang W, Zhang L, Zhang X, Tang Q, et al: MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7. Cancer Lett. 335:168–174. 2013.PubMed/NCBI View Article : Google Scholar
16	Wang C, Wang X, Su Z, Fei H, Liu X and Pan Q: MiR-25 promotes hepatocellular carcinoma cell growth, migration and invasion by inhibiting RhoGDI1. Oncotarget. 6:36231–36244. 2015.PubMed/NCBI View Article : Google Scholar
17	Caiazza C and Mallardo M: The Roles of miR-25 and its Targeted Genes in Development of Human Cancer. MicroRNA. 5:113–119. 2016.PubMed/NCBI View Article : Google Scholar
18	Deng T, Yuan Y, Zhang C, Zhang C, Yao W, Wang C, Liu R and Ba Y: Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis. Cell Physiol Biochem. 39:1716–1722. 2016.PubMed/NCBI View Article : Google Scholar
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
20	Hayes J, Peruzzi PP and Lawler S: MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol Med. 20:460–469. 2014.PubMed/NCBI View Article : Google Scholar
21	Song W, Li Q and Wang L and Wang L: Modulation of FoxO1 expression by miR-21 to promote growth of pancreatic ductal adenocarcinoma. Cell Physiol Biochem. 35:184–190. 2015.PubMed/NCBI View Article : Google Scholar
22	Sun XJ, Liu BY, Yan S, Jiang TH, Cheng HQ, Jiang HS, Cao Y and Mao AW: MicroRNA-29a Promotes Pancreatic Cancer Growth by Inhibiting Tristetraprolin. Cell Physiol Biochem. 37:707–718. 2015.PubMed/NCBI View Article : Google Scholar
23	Song B, Zheng K, Ma H, Liu A, Jing W, Shao C, Li G and Jin G: miR-429 determines poor outcome and inhibits pancreatic ductal adenocarcinoma growth by targeting TBK1. Cell Physiol Biochem. 35:1846–1856. 2015.PubMed/NCBI View Article : Google Scholar
24	Grove M, Demyanenko G, Echarri A, Zipfel PA, Quiroz ME, Rodriguiz RM, Playford M, Martensen SA, Robinson MR, Wetsel WC, et al: ABI2-deficient mice exhibit defective cell migration, aberrant dendritic spine morphogenesis, and deficits in learning and memory. Mol Cell Biol. 24:10905–10922. 2004.PubMed/NCBI View Article : Google Scholar